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Introduction 
Non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease in many counties. Overall, 
30-40% of patients with NAFLD develop progressive liver fibrosis, which can result in cirrhosis. 
Identifying patients who progress to advanced fibrosis/cirrhosis is important so they can be screened 
for liver-related complications. Cross sectional studies show that the NAFLD fibrosis score (NFS) and 
FIB-4 score can accurately rule out advanced fibrosis. It remains unknown whether longitudinal 
assessment of the NFS and FIB-4 scores can identify patients who progress to advanced fibrosis. Our 
aim was to assess the utility of the FIB-4 score and NFS at baseline and follow up to predict fibrosis 
progression from F0-2 to F3-4 and to identify F3-4. 
Methods:  
NAFLD patients with 2 sequential liver biopsies were identified from 7 European specialist centres. 
Clinical and laboratory data were collected from the time of liver biopsy. Histological scoring was 
performed according to the Kleiner criteria. The FIB-4 score and NFS were calculated from blood 
tests taken at the time of liver biopsy. 
Results 
From a total of 321 NAFLD patients who had sequential biopsies conducted >1 year apart, 278 
patients had stage 0-2 fibrosis at the index biopsy and 50 (18%) of them progressed to advanced 
fibrosis/cirrhosis (41 F3 and 9 F4) over median follow up time of 4.1 years (IQR 2.1-7.76). The 
proportion of patients progressing to F3-4 was 5%, 21% and 35% for patients with F0, F1 and F2 at 
baseline respectively. After multivariate analysis, the FIB-4 score (OR 2.01, 95% CI 1.28-3.4; p=0.003) 
was the only baseline factor that predicted progression from F0-2 to F3-4. The baseline FIB-4 score 
predicted progression to F3-4 with modest accuracy (AUROC 0.74, 95% CI 0.65-0.82; p<0.001; 
optimum cut-off 1.15, 71% sensitive and 69% specific; PPV 30% and NPV 93%). Both the FIB-4 score 
and the NFS identified patients who developed F3-4 at the follow up biopsy with reasonable 
accuracy (AUROC for FIB-4 0.76, 71% sensitivity and 67% specificity at cut-off 1.3; AUROC for NFS 
0.80, 83% sensitivity and 60% specificity at the cut off -1.455). Both the NFS and FIB-4 score were 
accurate in identifying patients who progressed to cirrhosis at the second biopsy (AUROC for NFS = 
0.85; AUROC for FIB4 0.85) 
Conclusions 
Longitudinal assessment of the NFS and FIB-4 score can identify patients who progress to advanced 
fibrosis/cirrhosis with reasonable accuracy. A low FIB-4 score (<1.15) in patients NAFLD can reliably 
exclude progression to advanced fibrosis over medium-term follow-up periods. 
